Literature DB >> 18777019

Antipsychotics possessing antidepressive efficacy increase Golf protein in rat striatum.

Hideki Taoka1, Takashi Hamamura, Shiro Endo, Shinji Miyata, Kishio Toma, Takeshi Ishihara, Shigetoshi Kuroda.   

Abstract

INTRODUCTION: Recently, second-generation antipsychotics (SGAs) have been widely used in the treatment of mood disorders. However, the mechanisms of the antidepressant effect of SGAs remain unclear. We proposed that Golf protein, a stimulant alpha-subunit of G protein coupled with the dopamine D1 receptor, might a play the key role in the antidepressive effect of antidepressants. To clarify the relationship between Golf protein and the antidepressive effects of antipsychotics, we examined the effects of chronic treatment with several antipsychotics on the level of Golf protein in the rat striatum.
MATERIALS AND METHODS: Male Wistar rats were treated with one of several antipsychotics for 2 weeks: olanzapine (2, 5, or 10 mg/kg), sulpiride (5, 10, or 50 mg/kg), amisulpride (3, 10, or 20 mg/kg), risperidone (0.2 or 2 mg/kg), haloperidol (0.3 or 3 mg/kg), or clozapine (2 or 10 mg/kg). RESULTS AND DISCUSSION: Olanzapine (5 mg/kg), sulpiride (5, or 10 mg/kg), and amisulpride (10 mg/kg) treatments significantly increased the level of Golf protein, but there was no increase with administration of higher doses of these three antipsychotics. Risperidone, haloperidol, and clozapine treatment did not change the level of Golf protein at any dose. In this study, all antipsychotics that have antidepressive effects increased Golf protein. This suggests that an increase in Golf may play an important role in the antidepressive effect of antipsychotics.
CONCLUSION: We postulate that the increase in Golf protein levels result in an increase the proportion of D1 receptors in the high-affinity state and that augmentation of the dopaminergic system exerts the antidepressant effect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18777019     DOI: 10.1007/s00213-008-1264-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  51 in total

Review 1.  The mesolimbic dopamine reward circuit in depression.

Authors:  Eric J Nestler; William A Carlezon
Journal:  Biol Psychiatry       Date:  2006-03-29       Impact factor: 13.382

2.  Faster response on amisulpride 50 mg versus sertraline 50-100 mg in patients with dysthymia or double depression: a randomized, double-blind, parallel group study.

Authors:  M Amore; M C Jori
Journal:  Int Clin Psychopharmacol       Date:  2001-11       Impact factor: 1.659

3.  Antidepressant action of sulpiride. Results of a placebo-controlled double-blind trial.

Authors:  E Rüther; D Degner; U Munzel; E Brunner; G Lenhard; J Biehl; U Vögtle-Junkert
Journal:  Pharmacopsychiatry       Date:  1999-07       Impact factor: 5.788

4.  Are D1 dopamine receptor agonists potential antidepressants?

Authors:  G Serra; M Collu; P D'Aquila; L Pani; G L Gessa
Journal:  Pharmacol Res Commun       Date:  1988-12

Review 5.  The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.

Authors:  Paul E Keck
Journal:  J Clin Psychiatry       Date:  2005       Impact factor: 4.384

Review 6.  Haloperidol alone or in combination for acute mania.

Authors:  A Cipriani; J M Rendell; J R Geddes
Journal:  Cochrane Database Syst Rev       Date:  2006-07-19

7.  Treatment of chronic depression with sulpiride: evidence of efficacy in placebo-controlled single case studies.

Authors:  W Maier; O Benkert
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

8.  A double-blind study of L-sulpiride versus amitriptyline in lithium-maintained bipolar depressives.

Authors:  A Bocchetta; F Bernardi; C Burrai; M Pedditzi; M Del Zompo
Journal:  Acta Psychiatr Scand       Date:  1993-12       Impact factor: 6.392

Review 9.  Update on augmentation of antidepressant response in resistant depression.

Authors:  Charles DeBattista; Anna Lembke
Journal:  Curr Psychiatry Rep       Date:  2005-12       Impact factor: 8.081

Review 10.  Newer treatment studies for bipolar depression.

Authors:  Keming Gao; Joseph R Calabrese
Journal:  Bipolar Disord       Date:  2005       Impact factor: 6.744

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.